RXULTI (Brexpiprazole)

What Is RXULTI and What Is It Used For?

RXULTI contains the active substance brexpiprazole, which belongs to a class of medications known as atypical (second-generation) antipsychotics. More specifically, brexpiprazole is described as a serotonin-dopamine activity modulator (SDAM) due to its unique pharmacological profile. It was developed by Otsuka Pharmaceutical in collaboration with H. Lundbeck A/S, the same partnership behind aripiprazole (Abilify), and was designed to build upon the partial dopamine agonist approach while addressing some of the limitations of earlier medications in this class.

Brexpiprazole was first approved by the United States Food and Drug Administration (FDA) in 2015 and subsequently by the European Medicines Agency (EMA) for use in the European Union. It is indicated for the treatment of schizophrenia, a chronic mental health condition characterized by positive symptoms (such as hallucinations, delusions, and disorganized speech), negative symptoms (such as social withdrawal, emotional flatness, and loss of motivation), and cognitive impairment. The medication is approved for both acute treatment and long-term maintenance therapy to prevent relapse.

What distinguishes brexpiprazole from its predecessor aripiprazole is its refined receptor binding profile. While both are partial agonists at dopamine D2 and serotonin 5-HT1A receptors and antagonists at serotonin 5-HT2A receptors, brexpiprazole demonstrates lower intrinsic activity at D2 receptors and stronger affinity for 5-HT1A receptors. It also has significant binding affinity for noradrenergic alpha-1B and alpha-2C receptors. This combination of pharmacological properties is thought to contribute to its favorable tolerability profile, particularly a potentially lower incidence of akathisia (inner restlessness) and activation-related symptoms compared to aripiprazole.

In clinical trials, brexpiprazole demonstrated statistically significant improvement in Positive and Negative Syndrome Scale (PANSS) total scores compared to placebo in patients with acute schizophrenia. The medication was effective in reducing both positive symptoms (hallucinations, delusions) and negative symptoms (social withdrawal, blunted affect), with improvement observed across multiple symptom domains. Importantly, relapse prevention studies showed that continued treatment with RXULTI significantly reduced the risk of impending relapse compared to switching to placebo.

RXULTI is approved for use in both adults and adolescents aged 13 years and older. In the United States, brexpiprazole also holds an FDA approval as adjunctive therapy for major depressive disorder (MDD) in adults, though this indication may not be available in all regulatory jurisdictions. The European approval is specifically for schizophrenia. In all cases, RXULTI is intended for use under close medical supervision, with regular monitoring of metabolic parameters, body weight, and psychiatric symptoms.

What Should You Know Before Taking RXULTI?

A thorough medical evaluation is essential before beginning treatment with RXULTI. Your doctor needs a complete picture of your medical history, current medications, and personal circumstances to determine whether brexpiprazole is the right choice for you and to establish appropriate monitoring during treatment. Open communication with your healthcare provider about all relevant factors is crucial for safe and effective use of this medication.

Contraindications

You should not take RXULTI if you are allergic (hypersensitive) to brexpiprazole or any of the other ingredients in the formulation (including lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropylcellulose, magnesium stearate, hypromellose, talc, and titanium dioxide). Signs of an allergic reaction may include swelling of the mouth, tongue, face, or throat, itching, hives, or difficulty breathing. If you experience any of these symptoms, seek emergency medical attention immediately.

Warnings and Precautions

Before starting RXULTI and throughout your treatment, tell your doctor if you have or have had any of the following conditions, as they may require special monitoring, dose adjustments, or alternative treatment:

• Neuroleptic malignant syndrome (NMS): Tell your doctor immediately if you experience a combination of fever, sweating, rapid breathing, muscle stiffness, and drowsiness or sleepiness. These may be signs of NMS, a rare but potentially life-threatening condition that requires immediate medical intervention including stopping the medication.
• Heart problems or stroke: Including irregular heartbeat, a condition called QT prolongation (detectable on ECG), or if anyone in your family has had irregular heart rhythm. Inform your doctor of all other medications that may prolong the QT interval, as well as any electrolyte imbalances.
• Low or high blood pressure: RXULTI can cause orthostatic hypotension (a drop in blood pressure when standing up), which may lead to dizziness, lightheadedness, or fainting. This risk is higher in elderly patients and those already taking blood pressure medications.
• Blood clots or family history of blood clots: Antipsychotic medications have been associated with venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Symptoms include leg swelling, pain, and redness, or chest pain and breathing difficulties.
• Low white blood cell count: If you have or have had a low white blood cell count, especially if caused by previous medication use, your doctor will regularly monitor blood counts. Conditions called leukopenia, neutropenia, and agranulocytosis can be life-threatening. Treatment will be stopped immediately if white blood cell counts fall too low.
• Diabetes or risk factors for diabetes: RXULTI can elevate blood glucose levels. Signs of hyperglycemia include excessive thirst, increased urination, increased appetite, and weakness. Patients with diabetes or risk factors should have regular blood glucose monitoring.
• Seizures (epilepsy): RXULTI may lower the seizure threshold. If you have a history of seizures or conditions that increase seizure risk, closer monitoring may be needed.
• Swallowing difficulties (dysphagia): RXULTI should be used with caution in patients who have difficulty swallowing, as antipsychotic medications can cause esophageal dysmotility and aspiration pneumonia.
• Movement disorders (extrapyramidal symptoms): These can include jerking movements, spasms, restlessness, or slow movements. Inform your doctor if you have experienced these previously or if they develop during treatment.
• Elevated prolactin levels: RXULTI can increase prolactin hormone levels. If you have a pituitary tumor or elevated prolactin, discuss this with your doctor before starting treatment.

Pregnancy and Breastfeeding

RXULTI is not recommended during pregnancy. If you are pregnant, think you might be pregnant, or are planning to become pregnant, consult your doctor before using this medication. Women of childbearing age should use effective contraception while taking RXULTI.

Neonates whose mothers took RXULTI during the last three months of pregnancy may experience withdrawal symptoms including tremor, rigid or floppy muscles, drowsiness, agitation, breathing difficulties, and feeding problems. If your baby develops any of these symptoms after birth, contact your healthcare provider immediately.

Brexpiprazole passes into breast milk. Discuss with your doctor the best way to feed your infant while taking RXULTI. Your doctor will weigh the benefits of treatment for you against the benefits of breastfeeding for your baby. Do not breastfeed while taking RXULTI without explicit medical advice.

Driving and Operating Machinery

RXULTI may affect your ability to drive and operate machinery. The medication can cause dizziness, drowsiness, and impaired reaction times. Do not drive a car or operate tools or machinery until you know how RXULTI affects you personally. If you experience any of these effects, refrain from activities that require full alertness until the symptoms resolve.

Important Information About Excipients

RXULTI tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, consult your doctor before taking this medicine.

How Does RXULTI Interact with Other Drugs?

Drug interactions with RXULTI are primarily related to its metabolism through the cytochrome P450 enzyme system, particularly CYP3A4 and CYP2D6. Brexpiprazole is metabolized by both of these enzymes, meaning that medications which inhibit or induce either pathway can significantly alter brexpiprazole blood levels. Additionally, combining RXULTI with other central nervous system (CNS) active substances, including alcohol, requires caution due to potential additive effects on sedation and cognitive impairment.

Always inform your doctor or pharmacist about all medications you are taking, have recently taken, or might take, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. This information is critical for preventing potentially dangerous interactions.

Major Interactions

The following drug interactions are clinically significant and typically require dose adjustments or careful monitoring:

Other Notable Interactions

Several additional medication categories warrant awareness when used alongside RXULTI:

• Antidepressants (SSRIs, SNRIs) and St. John’s Wort: Fluoxetine and paroxetine are strong CYP2D6 inhibitors that require RXULTI dose reduction. St. John’s Wort is a CYP3A4 inducer that may reduce RXULTI effectiveness. Other antidepressants may have milder interactions but should still be discussed with your doctor.
• Antifungal medications (ketoconazole, itraconazole): These strong CYP3A4 inhibitors significantly increase brexpiprazole levels. Dose reduction of RXULTI is required when co-administered.
• Anticonvulsants (carbamazepine, phenobarbital): These CYP3A4 inducers substantially reduce brexpiprazole levels, potentially making RXULTI less effective. Your doctor may need to increase the RXULTI dose.
• Tuberculosis medications (rifampicin): Rifampicin is a strong CYP3A4 inducer that markedly decreases brexpiprazole levels. Dose adjustment is essential during concurrent use.
• Antibiotics (clarithromycin): A strong CYP3A4 inhibitor that increases brexpiprazole levels, requiring dose reduction.
• CNS depressants (opioids, benzodiazepines, sedatives): Combining RXULTI with other CNS-active substances such as codeine, morphine, or sedating medications may cause increased sedation and drowsiness. Use only under close medical supervision.
• Diuretics (furosemide, bendroflumethiazide): These can cause electrolyte imbalances that may interact with RXULTI’s cardiac effects. Monitor electrolytes and cardiac function.
• Statins (simvastatin and others): Both RXULTI and statins can elevate creatine phosphokinase (CPK) levels. If you are taking both, inform your doctor about any unexplained muscle pain, tenderness, or weakness.
• Alcohol: Alcohol should be avoided while taking RXULTI because it can increase drowsiness, impair judgment, and worsen the underlying psychiatric condition.

What Is the Correct Dosage of RXULTI?

RXULTI dosage requires a gradual titration schedule over the first week of treatment. This step-wise approach helps minimize side effects, particularly dizziness, akathisia, and gastrointestinal symptoms, by allowing the body to adjust to increasing blood levels of brexpiprazole. Always follow your doctor’s or pharmacist’s instructions exactly regarding dosage. Do not change your dose without consulting your healthcare provider.

Adults

RXULTI tablets can be taken with or without food, as food does not significantly affect absorption. Swallow the tablet whole with water. If you were previously taking another antipsychotic medication, your doctor will decide whether to stop the other medication gradually or immediately and will adjust the RXULTI dose accordingly. Your doctor will also advise you on how to switch from RXULTI to other medications if needed.

Adolescents (13 Years and Older)

Kidney and Liver Impairment

If you have kidney problems, your doctor may need to adjust your RXULTI dose. The degree of dose adjustment depends on the severity of the renal impairment and should be determined by your prescribing physician based on your individual clinical situation.

Similarly, if you have liver problems, dose adjustment may be necessary. Hepatic impairment can affect the metabolism of brexpiprazole, potentially leading to higher blood levels. Your doctor will consider the severity of your liver disease when determining the appropriate dose.

Missed Dose

If you forget to take a dose of RXULTI, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to compensate for a missed one. If you forget two or more consecutive doses, contact your doctor for guidance on how to resume treatment, as the titration schedule may need to be restarted depending on how long the medication was interrupted.

Because RXULTI has a very long half-life (approximately 91 hours), missing a single dose is unlikely to cause dramatic changes in blood levels. However, consistent daily dosing is important for maintaining optimal therapeutic benefit.

Overdose

There is no specific antidote for brexpiprazole overdose. Treatment is supportive, with close monitoring of vital signs, cardiac function (including continuous ECG monitoring for QT prolongation and arrhythmias), and airway management. Medical supervision should continue until the patient has recovered. Activated charcoal may be considered if the patient presents early after ingestion and can safely protect their airway.

What Are the Side Effects of RXULTI?

Like all medications, RXULTI can cause side effects, although not everyone will experience them. The side effect profile of brexpiprazole has been extensively studied in clinical trials involving thousands of patients. Some side effects are mild and temporary, while others may be serious and require immediate medical attention. Understanding the potential side effects helps you recognize them early and communicate effectively with your healthcare provider.

The following side effects are organized by frequency based on clinical trial data and post-marketing reports from the European Medicines Agency (EMA) and the FDA:

If you experience any side effects, even those not listed above, talk to your doctor or pharmacist. Reporting suspected side effects helps regulatory authorities continuously monitor the benefit-risk balance of medications. You can report side effects through your national pharmacovigilance system or directly to the European Medicines Agency.

How Should You Store RXULTI?

Proper storage of RXULTI is important to ensure the medication remains effective and safe throughout its shelf life. Keep the tablets in their original blister packaging until you are ready to take them, as this protects them from light and moisture.

• Temperature: No special temperature storage conditions are required. Store at room temperature.
• Children: Keep RXULTI out of the sight and reach of children at all times.
• Expiry date: Do not use RXULTI after the expiry date stated on the outer carton and blister after “EXP”. The expiry date refers to the last day of that month.
• Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.

RXULTI film-coated tablets are supplied in aluminum/PVC blister packs containing 10, 28, or 56 tablets. Not all pack sizes may be marketed in your country.

What Does RXULTI Contain?

Each RXULTI film-coated tablet contains brexpiprazole as the active ingredient. The tablets are available in six different strengths, each identifiable by its distinctive color and imprint:

Inactive Ingredients

In addition to the active ingredient brexpiprazole, each tablet contains the following inactive ingredients:

• Tablet core: Lactose monohydrate, corn starch, microcrystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, magnesium stearate, purified water
• Film coating: Hypromellose (E 464), talc (E 553b), titanium dioxide (E 171)
• Coloring agents (vary by strength): Iron oxides (E 172) in yellow, red, and/or black combinations depending on the tablet strength

RXULTI is manufactured by Otsuka Pharmaceutical Netherlands B.V. (marketing authorization holder), with manufacturing sites including Elaiapharm in Valbonne, France, and H. Lundbeck A/S in Valby, Denmark.